| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| TransCode Therapeutics Inc. | TTX-MC138 - (PRE-I-SPY) | Metastatic solid tumors | Phase 2a | Trial Planned | Intravenous | Oncology |
| Travere Therapeutics Inc. | FILSPARI (sparsentan) | Focal segmental glomerulosclerosis (FSGS) | PDUFA | Ongoing | Oral | #N/A |
| Travere Therapeutics Inc. | Sparsentan - (DUPLEX) | Focal segmental glomerulosclerosis (FSGS) | NDA Filing | Ongoing | Oral | #N/A |
| Travere Therapeutics Inc. | Pegtibatinase (TVT-058) - (HARMONY) | Classical homocystinuria (HCU) | Phase 3 | Clinical Pause | Intravenous | Genetic Disorder |
| Travere Therapeutics Inc. | Chenodal (chenodeoxycholic acid) | Cerebrotendinous xanthomatosis (CTX) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Travere Therapeutics Inc. | Fosmetpantotenate | Pantothenate kinase-associated neurodegeneration (PKAN) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Travere Therapeutics Inc. | CNSA-001 | Phenylketonuria (PKU) | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Travere Therapeutics Inc. | Sparsentan - (EPPIK) | Pediatric Patients with Selected Proteinuric Glomerular Diseases | Phase 2 | Ongoing | Oral | #N/A |